• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Bedaquiline, pretomanid, and linezolid with or without moxifloxacin for tuberculosis.

作者信息

Labuda Sarah M, Seaworth Barbara, Dasgupta Shom, Goswami Neela D

机构信息

US Centers for Disease Control and Prevention, Division of Tuberculosis Elimination, Atlanta, GA 30329, USA.

Heartland National Tuberculosis Center, San Antonio, TX, USA.

出版信息

Lancet Respir Med. 2024 Feb;12(2):e5-e6. doi: 10.1016/S2213-2600(23)00426-5. Epub 2023 Nov 30.

DOI:10.1016/S2213-2600(23)00426-5
PMID:38043563
Abstract
摘要

相似文献

1
Bedaquiline, pretomanid, and linezolid with or without moxifloxacin for tuberculosis.贝达喹啉、普瑞马尼德以及利奈唑胺联合或不联合莫西沙星用于治疗结核病。
Lancet Respir Med. 2024 Feb;12(2):e5-e6. doi: 10.1016/S2213-2600(23)00426-5. Epub 2023 Nov 30.
2
Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in Europe.在欧洲，利福平耐药结核病的贝达喹啉、普托马尼德、利奈唑胺和莫西沙星（BPaL（M））方案的药物供应和耐药检测情况。
Clin Microbiol Infect. 2024 Sep;30(9):1197.e1-1197.e4. doi: 10.1016/j.cmi.2024.03.009. Epub 2024 Mar 13.
3
Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in Europe: author's response.欧洲用于耐利福平结核病的贝达喹啉、普瑞玛尼、利奈唑胺和莫西沙星（BPaL(M)）方案的药物供应及耐药性检测：作者回应
Clin Microbiol Infect. 2024 Sep;30(9):1207-1208. doi: 10.1016/j.cmi.2024.06.009. Epub 2024 Jun 18.
4
Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis.贝达喹啉联合利奈唑胺或莫西沙星与吡嗪酰胺对鼠结核模型的新型方案的贡献。
Antimicrob Agents Chemother. 2019 Apr 25;63(5). doi: 10.1128/AAC.00021-19. Print 2019 May.
5
A bedaquiline, pretomanid, moxifloxacin, and pyrazinamide regimen for drug-susceptible and drug-resistant tuberculosis.用于药物敏感和耐药结核病的贝达喹啉、普瑞玛胺、莫西沙星和吡嗪酰胺治疗方案。
Lancet Infect Dis. 2024 Sep;24(9):940-941. doi: 10.1016/S1473-3099(24)00257-3. Epub 2024 May 17.
6
Availability of drugs for the treatment of multidrug-resistant/rifampicin-resistant tuberculosis in the World Health Organization European Region, October 2023.2023 年 10 月，世界卫生组织欧洲区域耐多药/利福平耐药结核病治疗药物的供应情况。
Euro Surveill. 2024 Apr;29(17). doi: 10.2807/1560-7917.ES.2024.29.17.2400211.
7
Next-Generation Diarylquinolines Improve Sterilizing Activity of Regimens with Pretomanid and the Novel Oxazolidinone TBI-223 in a Mouse Tuberculosis Model.下一代二芳基喹啉类药物提高贝达喹啉和新型噁唑烷酮类药物 TBI-223 方案在小鼠结核病模型中的杀菌活性。
Antimicrob Agents Chemother. 2023 Apr 18;67(4):e0003523. doi: 10.1128/aac.00035-23. Epub 2023 Mar 15.
8
Bactericidal and sterilizing activity of novel regimens combining bedaquiline or TBAJ-587 with GSK2556286 and TBA-7371 in a mouse model of tuberculosis.新型联合方案贝达喹啉或 TBAJ-587 联合 GSK2556286 和 TBA-7371 在结核分枝杆菌感染小鼠模型中的杀菌和灭菌活性。
Antimicrob Agents Chemother. 2024 Apr 3;68(4):e0156223. doi: 10.1128/aac.01562-23. Epub 2024 Feb 20.
9
Long-Term Effects on QT Prolongation of Pretomanid Alone and in Combinations in Patients with Tuberculosis.利奈唑胺单药及联合治疗对结核病患者 QT 间期延长的长期影响。
Antimicrob Agents Chemother. 2019 Sep 23;63(10). doi: 10.1128/AAC.00445-19. Print 2019 Oct.
10
[Advances in antibiotic therapy for tuberculosis].[结核病抗生素治疗的进展]
Rev Prat. 2024 Mar;74(3):239-244.

引用本文的文献

1
Improved Radiosynthesis of [F]-Labeled Oxazolidinone Antibiotics for Future Clinical Translation.用于未来临床转化的[F]标记恶唑烷酮类抗生素的改进放射性合成
ACS Infect Dis. 2025 Jul 11;11(7):2009-2017. doi: 10.1021/acsinfecdis.5c00292. Epub 2025 Jun 12.
2
Long term outcomes in drug resistant tuberculosis with Bedaquiline, Pretomanid and varying doses of Linezolid.使用贝达喹啉、普瑞玛尼和不同剂量利奈唑胺治疗耐多药结核病的长期疗效
J Infect. 2025 Jul;91(1):106509. doi: 10.1016/j.jinf.2025.106509. Epub 2025 May 15.
3
Advancing against drug-resistant tuberculosis: an extensive review, novel strategies and patent landscape.
对抗耐药结核病的进展：全面综述、新策略及专利态势
Naunyn Schmiedebergs Arch Pharmacol. 2025 Mar;398(3):2127-2150. doi: 10.1007/s00210-024-03466-0. Epub 2024 Oct 8.
4
Efficacy and safety of shorter multidrug-resistant or rifampicin-resistant tuberculosis regimens: a network meta-analysis.较短疗程的耐多药或耐利福平结核病治疗方案的疗效与安全性：一项网状Meta分析
BMC Infect Dis. 2024 Oct 1;24(1):1087. doi: 10.1186/s12879-024-09960-3.
5
Antibacterial efficacy of mycobacteriophages against virulent Mycobacterium tuberculosis.噬菌体对毒力结核分枝杆菌的抗菌效果。
BMC Microbiol. 2024 Sep 4;24(1):320. doi: 10.1186/s12866-024-03474-3.